Chief Medical Officer
Debora Barton brings 20 years of oncology experience, both in academia as a practicing physician and in the biotechnology/pharmaceutical industry developing clinical trials for cancer patients. As the Chief Medical Officer of Carisma Therapeutics, she is now working on the development of the first in class cell therapy CAR-macrophage for the treatment of solid tumors, including HER2 positive Breast Cancer. She also collaborates with the American Cancer Society – Manhattan Chapter as a Board Member.
Most recently, she has served in key senior executive positions in cellular therapy and radiopharmaceutical biotech companies including Iovance Biotherapeutics and Advanced Accelerator Applications, acquired by Novartis during Debora’s tenure. In her leadership roles, Debora built Clinical Development and Drug Safety teams setting up infrastructure for the conduct of clinical studies and was instrumental in obtaining FDA Breakthrough Designation for a cell therapy product and in the approval of a radiopharmaceutical agent by both FDA and EMA.
Previously, Debora spent 10 years at Celgene and Novartis, always focusing on improving the lives of cancer patients. She holds an MD from Pontificia Universidade Catolica Sao Paulo (PUC-SP) and completed her fellowship in Oncology at Federal University of Sao Paulo (UNIFESP) in Brazil.